NHMRC grant success – women’s health research

Federal Minister for Health, The Hon. Greg Hunt MP has announced $18 million in National Health and Medical Research Council (NHMRC) funding for women’s health research.

Hudson Institute scientists have been awarded a total of more than $1 million in Fellowship and Development Grant funding in the announcement.

Congratulations to Dr Tracey Edgell, Dr Vanesa Stojanovska and Dr Sarah Marshall on being awarded funding in support of their life-changing medical research into IVF, pre-eclampsia and preterm brain injury.

NHMRC Development Grant

Dr Tracey Edgell
Development Grant: 2019 – 2020
Validation of a prognostic assay for embryo transfer outcome

This study will provide strong evidence of the usefulness of a simple blood test to predict the likelihood of a successful IVF embryo transfer.  Blood samples from IVF centres in Australia and Singapore will be collected and used to assess the reliability of  a previously developed serum signature in predicting the outcome of embryo transfer. This will aid clinical decision-making in the treatment of infertile women, improve IVF success rates and reduce both financial and emotional costs.

NHMRC Early Career Fellowship

Dr Vanesa Stojanovska
Peter Doherty Biomedical Fellowship: 2019 – 2022
Improving breathing of preterm newborns exposed to inflammation during pregnancy

Preterm babies exposed to inflammation during pregnancy have a high incidence of breathing difficulties and brain injury, which often lead to cerebral palsy. Dr Stojanovska’s research aims to investigate whether inflammation injures the fetal brainstem – a life-sustaining brain region which controls our breathing, and whether anti-inflammatory treatments can protect against this injury. Outcomes of this work will guide clinical trials focused on reducing the burden of preterm brain injury.

Dr Sarah Marshall
Peter Doherty Biomedical Fellowship: 2019 – 2022
Developing New Treatments for Severe Pre-eclampsia

Pre-eclampsia is a serious pregnancy condition affecting 1 in 20 pregnant women worldwide. Dr Marshall and her team have identified numerous potential treatment targets for these women, which need further investigation. This research program will harness new insights into the vascular mechanisms of this disease, while assessing and generating new therapies. Successful completion of this work could produce new treatments for pre-eclampsia and reduce the burden of disease for  mother and baby.